89 related articles for article (PubMed ID: 23560836)
1. Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?
Franco R; Rocco G; Marino FZ; Pirozzi G; Normanno N; Morabito A; Sperlongano P; Stiuso P; Luce A; Botti G; Caraglia M
Expert Rev Anticancer Ther; 2013 Apr; 13(4):407-20. PubMed ID: 23560836
[TBL] [Abstract][Full Text] [Related]
2. Targeting anaplastic lymphoma kinase in lung cancer.
Shaw AT; Solomon B
Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
[TBL] [Abstract][Full Text] [Related]
3. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
4. Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.
Dagogo-Jack I; Shaw AT; Riely GJ
Clin Pharmacol Ther; 2017 May; 101(5):625-633. PubMed ID: 28182271
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic lymphoma kinase as a therapeutic target.
Kruczynski A; Delsol G; Laurent C; Brousset P; Lamant L
Expert Opin Ther Targets; 2012 Nov; 16(11):1127-38. PubMed ID: 22998583
[TBL] [Abstract][Full Text] [Related]
6. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
7. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
D'Arcangelo M; Wynes MW; Hirsch FR
Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
[TBL] [Abstract][Full Text] [Related]
8. Virtual screening and further development of novel ALK inhibitors.
Okamoto M; Kojima H; Saito N; Okabe T; Masuda Y; Furuya T; Nagano T
Bioorg Med Chem; 2011 May; 19(10):3086-95. PubMed ID: 21515061
[TBL] [Abstract][Full Text] [Related]
9. ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.
Ahn HK; Han B; Lee SJ; Lim T; Sun JM; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2012 May; 76(2):253-4. PubMed ID: 22385925
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy for NSCLC: ALK inhibition.
Pearson R; Kolesar JM
J Oncol Pharm Pract; 2012 Jun; 18(2):271-4. PubMed ID: 21844131
[TBL] [Abstract][Full Text] [Related]
11. Journey of the ALK-inhibitor CH5424802 to phase II clinical trial.
Latif M; Saeed A; Kim SH
Arch Pharm Res; 2013 Sep; 36(9):1051-4. PubMed ID: 23700294
[TBL] [Abstract][Full Text] [Related]
12. Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metastases.
Kim H; Xu X; Yoo SB; Sun PL; Jin Y; Paik JH; Choe G; Jheon S; Lee CT; Chung JH
Histopathology; 2013 Jan; 62(2):305-14. PubMed ID: 23020707
[TBL] [Abstract][Full Text] [Related]
13. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.
Lee JK; Kim TM; Koh Y; Lee SH; Kim DW; Jeon YK; Chung DH; Yang SC; Kim YT; Kim YW; Heo DS; Bang YJ
Lung Cancer; 2012 Aug; 77(2):460-3. PubMed ID: 22622260
[TBL] [Abstract][Full Text] [Related]
14. Treatment of ALK-positive non-small cell lung cancer.
Bang YJ
Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802).
Kinoshita K; Asoh K; Furuichi N; Ito T; Kawada H; Hara S; Ohwada J; Miyagi T; Kobayashi T; Takanashi K; Tsukaguchi T; Sakamoto H; Tsukuda T; Oikawa N
Bioorg Med Chem; 2012 Feb; 20(3):1271-80. PubMed ID: 22225917
[TBL] [Abstract][Full Text] [Related]
16. The anaplastic lymphoma kinase testing conundrum.
Conde E; Taniere P; Lopez-Rios F
Expert Rev Mol Diagn; 2015 Feb; 15(2):161-3. PubMed ID: 25579121
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.
af Gennäs GB; Mologni L; Ahmed S; Rajaratnam M; Marin O; Lindholm N; Viltadi M; Gambacorti-Passerini C; Scapozza L; Yli-Kauhaluoma J
ChemMedChem; 2011 Sep; 6(9):1680-92. PubMed ID: 21721129
[TBL] [Abstract][Full Text] [Related]
19. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
Li R; Morris SW
Med Res Rev; 2008 May; 28(3):372-412. PubMed ID: 17694547
[TBL] [Abstract][Full Text] [Related]
20. ALKoma: a cancer subtype with a shared target.
Mano H
Cancer Discov; 2012 Jun; 2(6):495-502. PubMed ID: 22614325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
